Poseida Therapeutics, Inc. announced that Kristin Yarema, Ph.D., has joined the Company as President, Cell Therapy effective 12 April 2023. Throughout her career in the biopharmaceutical industry, Dr. Yarema has led product strategy and commercialization for therapies at all stages of their life cycle. She joins Poseida after most recently serving as Chief Commercial Officer at Atara Biotherapeutics, where she led the commercialization of EBVALLOTM, which became the world's first marketed allogeneic T cell therapy after receiving regulatory approval in Europe for the treatment of a rare lymphoma.

She also drove product and portfolio strategy and commercialization for allogeneic pipeline therapies including CAR-Ts for liquid and solid tumors, as well as allogeneic T cell therapy for multiple sclerosis and other autoimmune diseases. Immediately prior to her time at Atara, she held a series of U.S. and global commercial leadership roles at Amgen, including most recently Vice President Therapeutic Area Head for Global Product Strategy Commercial Innovation in Hematology-Oncology, where her work included CAR-T, T cell engagers, and other innovative therapies. Dr. Yarema also served in commercial VP roles for many other brands and pipeline assets within Amgen's portfolio, including those in neuroscience and autoimmune diseases, and initiated programs in rare and orphan diseases.

Earlier in her career, Dr. Yarema held a variety of roles at Novartis and McKinsey Company, where she led commercialization, portfolio planning, strategy, clinical development including for an orphan disease development program, and pricing and reimbursement projects for the companies across the U.S., Europe, and Asia. Dr. Yarema earned a Ph.D. in Biochemical Engineering from University of California, Berkeley and is a graduate of Stanford University, where she earned dual bachelor's degrees in Chemical Engineering and English. In addition, she serves on the boards of directors of the Celiac Disease Foundation, a U.S.-based patient advocacy group, and the Alliance for Regenerative Medicine, the cell and gene therapy industry association.